Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (732) 732
Publication (82) 82
Book Chapter (7) 7
Book Review (3) 3
Conference Proceeding (2) 2
Magazine Article (2) 2
Dissertation (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
simeprevir (517) 517
humans (512) 512
index medicus (490) 490
hepatitis c (341) 341
hepatitis c, chronic - drug therapy (331) 331
antiviral agents - therapeutic use (328) 328
ribavirin (319) 319
sofosbuvir (308) 308
hepatitis c virus (290) 290
male (281) 281
female (261) 261
drug therapy, combination (258) 258
middle aged (255) 255
gastroenterology & hepatology (247) 247
hepacivirus - genetics (239) 239
genotype (230) 230
treatment outcome (185) 185
interferon (181) 181
treatment-naive patients (179) 179
aged (177) 177
adult (160) 160
ribavirin - therapeutic use (158) 158
pegylated interferon (155) 155
simeprevir - therapeutic use (145) 145
hepacivirus - drug effects (142) 142
hepatitis (140) 140
hepatitis c - drug therapy (136) 136
telaprevir (136) 136
antiviral agents - administration & dosage (134) 134
antiviral agents (133) 133
antiviral agents - adverse effects (128) 128
daclatasvir (123) 123
hepatitis c, chronic - virology (118) 118
hcv (114) 114
pharmacology & pharmacy (113) 113
sustained virological response (113) 113
health aspects (112) 112
virus-infection (111) 111
therapy (110) 110
infection (108) 108
cirrhosis (106) 106
liver (104) 104
plus ribavirin (102) 102
ledipasvir (100) 100
genotype 1 infection (99) 99
infectious diseases (98) 98
sofosbuvir - therapeutic use (98) 98
double-blind (96) 96
genotype 1 (95) 95
liver cirrhosis (95) 95
care and treatment (94) 94
sulfonamides - therapeutic use (93) 93
biological response modifiers (91) 91
analysis (90) 90
liver transplantation (90) 90
protease inhibitors (88) 88
interferon-alpha - therapeutic use (85) 85
genetic aspects (84) 84
transplantation (83) 83
sustained virologic response (82) 82
drug therapy (80) 80
heterocyclic compounds, 3-ring - therapeutic use (80) 80
boceprevir (79) 79
ribavirin - administration & dosage (78) 78
simeprevir - administration & dosage (77) 77
direct-acting antivirals (75) 75
uridine monophosphate - analogs & derivatives (74) 74
hepatitis c, chronic - complications (73) 73
chronic hepatitis c (70) 70
simeprevir - adverse effects (64) 64
interferon-alpha 2a (63) 63
patients (63) 63
polyethylene glycols - therapeutic use (63) 63
retrospective studies (62) 62
genotype & phenotype (61) 61
infections (60) 60
recurrence (60) 60
sofosbuvir - administration & dosage (60) 60
virology (59) 59
virus diseases (59) 59
antiviral agents - pharmacology (58) 58
protease inhibitors - therapeutic use (57) 57
proteases (57) 57
gastroenterology and hepatology (56) 56
medicine, general & internal (56) 56
viral nonstructural proteins - antagonists & inhibitors (56) 56
young adult (56) 56
treatment-naive (55) 55
protease inhibitor (54) 54
recombinant proteins - therapeutic use (54) 54
safety (54) 54
hepatitis c - virology (53) 53
hepatology (53) 53
ribavirin - adverse effects (53) 53
peginterferon (52) 52
simeprevir plus sofosbuvir (52) 52
hepacivirus - isolation & purification (50) 50
uridine monophosphate - therapeutic use (50) 50
antiviral therapy (48) 48
hepacivirus (48) 48
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (690) 690
German (10) 10
Russian (9) 9
Hungarian (8) 8
Japanese (7) 7
Korean (5) 5
Spanish (4) 4
Czech (3) 3
French (3) 3
Italian (1) 1
Polish (1) 1
Swedish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Safety and efficacy of sofosbuvir‐containing regimens in hepatitis C‐infected patients with impaired renal function
by Saxena, Varun and Koraishy, Farrukh M and Sise, Meghan E and Lim, Joseph K and Schmidt, Monica and Chung, Raymond T and Liapakis, Annmarie and Nelson, David R and Fried, Michael W and Terrault, Norah A and HCV-TARGET
Liver International, ISSN 1478-3223, 06/2016, Volume 36, Issue 6, pp. 807 - 816
Background & Aims Renal clearance is the major elimination pathway for sofosbuvir (SOF). We assessed the safety and efficacy of SOF‐containing regimens in... 
haemodialysis | decompensated cirrhosis | sustained virologic response | liver transplantation | Decompensated cirrhosis | Haemodialysis | Sustained virologic response | Liver transplantation | LIVER-TRANSPLANTATION | TELAPREVIR | SIMEPREVIR | RIBAVIRIN | COMBINATION | THERAPY | CIRRHOSIS | DISEASE | GASTROENTEROLOGY & HEPATOLOGY | Multivariate Analysis | Humans | Middle Aged | Hepacivirus - genetics | Male | Hepatitis C, Chronic - complications | North America | Simeprevir - adverse effects | Young Adult | Renal Insufficiency, Chronic - therapy | Simeprevir - administration & dosage | Aged, 80 and over | Adult | Female | Sofosbuvir - adverse effects | Drug Therapy, Combination | Databases, Factual | Glomerular Filtration Rate | Liver Cirrhosis - complications | Europe | Hepatitis C, Chronic - drug therapy | Antiviral Agents - administration & dosage | Renal Insufficiency, Chronic - physiopathology | Regression Analysis | Sofosbuvir - administration & dosage | Antiviral Agents - adverse effects | Adolescent | Aged | Sustained Virologic Response | Longitudinal Studies | Renal Dialysis | Transplantation of organs, tissues, etc | Hepatitis C | Anemia | Liver cirrhosis | Analysis | Liver
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Hepatitis B Virus Reactivation during Successful Treatment of Hepatitis C Virus with Sofosbuvir and Simeprevir
by Collins, Jeffrey M and Raphael, Kara Loren and Terry, Charles and Cartwright, Emily J and Pillai, Anjana and Anania, Frank A and Farley, Monica M
Clinical Infectious Diseases, ISSN 1058-4838, 10/2015, Volume 61, Issue 8, pp. 1304 - 1306
Treatment of hepatitis C virus with potent, interferon-free, direct-acting antiviral regimens with no activity against hepatitis B virus (HBV) may increase the... 
Simeprevir | HBV/HCV coinfection | Acute hepatitis | HBV reactivation | Sofosbuvir | INFECTIOUS DISEASES | CHRONIC INFECTION | COINFECTION | MICROBIOLOGY | RIBAVIRIN | IMMUNOLOGY | sofosbuvir | INTERFERON | simeprevir | THERAPY | acute hepatitis | Sofosbuvir - therapeutic use | Coinfection | Administration, Oral | Antiviral Agents - therapeutic use | Humans | Middle Aged | Risk Factors | Hepatitis B - virology | Hepatitis C, Chronic - virology | Male | Hepatitis C, Chronic - complications | Hepatitis C, Chronic - drug therapy | Antiviral Agents - administration & dosage | Hepatitis B virus - physiology | Simeprevir - therapeutic use | Hepatitis B - complications | Simeprevir - administration & dosage | Sofosbuvir - administration & dosage | Drug Therapy, Combination | Hepatitis | Care and treatment | Research | Hepatitis C virus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Daclatasvir plus simeprevir with or without ribavirin for the treatment of chronic hepatitis C virus genotype 1 infection
by Zeuzem, Stefan and Hézode, Christophe and Bronowicki, Jean-Pierre and Loustaud-Ratti, Veronique and Gea, Francisco and Buti, Maria and Olveira, Antonio and Banyai, Tivadar and Al-Assi, M. Tarek and Petersen, Joerg and Thabut, Dominique and Gadano, Adrian and Pruitt, Ronald and Makara, Mihály and Bourlière, Marc and Pol, Stanislas and Beumont-Mauviel, Maria and Ouwerkerk-Mahadevan, Sivi and Picchio, Gaston and Bifano, Marc and M Phee, Fiona and Boparai, Navdeep and Cheung, Kin and Hughes, Eric A and Noviello, Stephanie and LEAGUE-1 Study Team
Journal of Hepatology, ISSN 0168-8278, 2015, Volume 64, Issue 2, pp. 292 - 300
Graphical abstract 
Gastroenterology and Hepatology | Daclatasvir | Simeprevir | Direct-acting antiviral | Genotype 1 | NS5A inhibitor | All-oral therapy | Hepatitis C virus | NS3 protease inhibitor | Hepatitis C virus; Genotype 1 | CHRONIC HCV | SOFOSBUVIR | LEDIPASVIR | PEGYLATED INTERFERON | GASTROENTEROLOGY & HEPATOLOGY | TREATMENT-NAIVE PATIENTS | EPIDEMIOLOGY | Hepacivirus - drug effects | Drug Administration Schedule | Humans | Imidazoles - adverse effects | Middle Aged | Hepacivirus - genetics | Hepatitis C, Chronic - virology | Imidazoles - administration & dosage | DNA, Viral - analysis | Genotype | Male | Treatment Outcome | Hepatitis C, Chronic - drug therapy | Antiviral Agents - administration & dosage | Simeprevir - adverse effects | Dose-Response Relationship, Drug | Simeprevir - administration & dosage | Ribavirin - adverse effects | Antiviral Agents - adverse effects | Ribavirin - administration & dosage | Adult | Female | Aged | Drug Monitoring | Health aspects | Genetic aspects | Antiviral Agents | Hepatitis C, Chronic | Ribavirin | Life Sciences | Imidazoles | DNA, Viral | Hepacivirus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Safety and Efficacy of Simeprevir/Sofosbuvir in Hepatitis C–Infected Patients With Compensated and Decompensated Cirrhosis
by Saxena, Varun and Nyberg, Lisa and Pauly, Marypat and Dasgupta, Aditi and Nyberg, Anders and Piasecki, Barbara and Winston, Bradley and Redd, Jacquelyn and Ready, Joanna and Terrault, Norah A
Hepatology, ISSN 0270-9139, 09/2015, Volume 62, Issue 3, pp. 715 - 725
Risks and benefits of simeprevir plus sofosbuvir (SIM+SOF) in patients with advanced cirrhosis are unknown. We assessed the safety and sustained virological... 
GENOTYPE 1 | LIVER-TRANSPLANTATION | VIRUS-INFECTION | TREATMENT-NAIVE | SOFOSBUVIR | SIMEPREVIR | OPEN-LABEL | RIBAVIRIN | GASTROENTEROLOGY & HEPATOLOGY | Multivariate Analysis | Follow-Up Studies | Hepatitis C - drug therapy | Humans | Middle Aged | Male | Reference Values | Case-Control Studies | Simeprevir - adverse effects | Simeprevir - administration & dosage | Ribavirin - administration & dosage | Patient Safety | Female | Retrospective Studies | Sofosbuvir - adverse effects | Drug Therapy, Combination | Hepacivirus - drug effects | Severity of Illness Index | Liver Cirrhosis - drug therapy | Risk Assessment | Logistic Models | Treatment Outcome | Antiviral Agents - administration & dosage | Analysis of Variance | Sofosbuvir - administration & dosage | Ribavirin - adverse effects | Liver Cirrhosis - pathology | Aged | Hepatitis C - pathology | Liver Cirrhosis - physiopathology | Confidence intervals | Hepatitis | Multivariate analysis | Liver cirrhosis | Model of end stage liver disease | Adverse events | Child-Pugh class | Sustained virologic response
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Real-World Sustained Virologic Response Rates of Sofosbuvir-Containing Regimens in Patients Coinfected with Hepatitis C and HIV
by Del Bello, David and Cha, Agnes and Sorbera, Maria and Bichoupan, Kian and Levine, Calley and Doyle, Erin and Harty, Alyson and Patel, Neal and Ng, Michel and Gardenier, Donald and Odin, Joseph and Schiano, Thomas D and Fierer, Daniel S and Berkowitz, Leonard and Perumalswami, Ponni V and Dieterich, Douglas T and Branch, Andrea D
Clinical Infectious Diseases, ISSN 1058-4838, 06/2016, Volume 62, Issue 12, pp. 1497 - 1504
Background. Patients with hepatitis C virus (HCV) with or without human immunodeficiency virus (HIV) achieve high sustained virological response (SVR) rates on... 
sofosbuvir | simeprevir | HIV | hepatitis C | INFECTIOUS DISEASES | PLUS RIBAVIRIN | ABT-450/R-OMBITASVIR | MICROBIOLOGY | VIRUS GENOTYPE 1 | OPEN-LABEL | IMMUNOLOGY | THERAPY | DASABUVIR | INFECTED PATIENTS | HCV | PROGRESSION | PHASE-2 TRIAL | HIV-1 | Hepatitis C - drug therapy | HIV Infections - epidemiology | Humans | Middle Aged | Male | Simeprevir - therapeutic use | Simeprevir - adverse effects | Viral Load | Simeprevir - administration & dosage | Hepatitis C - epidemiology | Female | Sofosbuvir - adverse effects | Sofosbuvir - therapeutic use | Antiviral Agents - therapeutic use | HIV Infections - virology | Risk Factors | Treatment Outcome | Antiviral Agents - administration & dosage | Sofosbuvir - administration & dosage | Antiviral Agents - adverse effects | Hepatitis C - virology | HIV Infections - drug therapy | New York City - epidemiology | Hepacivirus | Care and treatment | Research | Hepatitis C | HIV (Viruses) | and Commentaries
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Sofosbuvir and simeprevir in hepatitis C genotype 1‐patients with end‐stage renal disease on haemodialysis or GFR <30 ml/min
by Nazario, Hector E and Ndungu, Milka and Modi, Apurva A
Liver International, ISSN 1478-3223, 06/2016, Volume 36, Issue 6, pp. 798 - 801
Background & Aims Treating chronic hepatitis C (CHC) in patients with end‐stage renal disease (ESRD) has suboptimal tolerability and cure rates. Safety and... 
sofosbuvir | Cirrhosis | Chronic hepatitis C | end‐stage renal disease | simeprevir | severe renal impairment | kidney transplant | renal failure | liver transplantation | End-stage renal disease | Simeprevir | Kidney transplant | Severe renal impairment | Renal failure | Sofosbuvir | Liver transplantation | VIRUS-INFECTION | TELAPREVIR | RIBAVIRIN | end-stage renal disease | HCV | GASTROENTEROLOGY & HEPATOLOGY | TREATMENT-NAIVE PATIENTS | Glomerular Filtration Rate | Liver Cirrhosis - complications | Humans | Middle Aged | Hepacivirus - genetics | Male | Hepatitis C, Chronic - complications | Hepatitis C, Chronic - drug therapy | Antiviral Agents - administration & dosage | Simeprevir - adverse effects | Kidney Failure, Chronic - therapy | Simeprevir - administration & dosage | Sofosbuvir - administration & dosage | Antiviral Agents - adverse effects | Texas | Kidney Failure, Chronic - complications | Female | Aged | Sofosbuvir - adverse effects | Sustained Virologic Response | Drug Therapy, Combination | Renal Dialysis | Chronic kidney failure | Analysis | Liver | Transplantation of organs, tissues, etc | Genetic aspects | Hepatitis C | Liver cirrhosis
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Efficacy and safety of direct acting antivirals in kidney transplant recipients with chronic hepatitis C virus infection
by Lin, Ming V and Sise, Meghan E and Pavlakis, Martha and Amundsen, Beth M and Chute, Donald and Rutherford, Anna E and Chung, Raymond T and Curry, Michael P and Hanifi, Jasmine M and Gabardi, Steve and Chandraker, Anil and Heher, Eliot C and Elias, Nahel and Riella, Leonardo V
PLoS ONE, ISSN 1932-6203, 07/2016, Volume 11, Issue 7, p. e0158431
The prevalence of Hepatitis C Virus (HCV) infection is significantly higher in patients with end-stage renal disease compared to the general population and... 
RENAL-REPLACEMENT THERAPY | GENOTYPE 1 | SURVIVAL | IMPACT | METAANALYSIS | HIV | SOFOSBUVIR | MULTIDISCIPLINARY SCIENCES | DISEASE | SIMEPREVIR | HCV | Humans | Middle Aged | Male | Hepatitis C, Chronic - complications | Simeprevir - therapeutic use | Transplant Recipients | Simeprevir - adverse effects | Adult | Female | Retrospective Studies | Sofosbuvir - adverse effects | Drug Therapy, Combination | Sofosbuvir - therapeutic use | Liver Cirrhosis - drug therapy | Kidney Failure, Chronic - surgery | Antiviral Agents - therapeutic use | Liver Cirrhosis - complications | Ribavirin - therapeutic use | Treatment Outcome | Kidney Transplantation | Hepatitis C, Chronic - drug therapy | Ribavirin - adverse effects | Antiviral Agents - adverse effects | Kidney Failure, Chronic - complications | Aged | Antiviral agents | Complications and side effects | Care and treatment | Chronic kidney failure | Patient outcomes | Organ transplant recipients | Dosage and administration | Research | Health aspects | Therapy | End-stage renal disease | Nephrology | Transplants & implants | Hemodialysis | Calcineurin | Medical services | Calcineurin inhibitors | Chronic infection | Viruses | Transplantation | Infections | Ribavirin | Medical schools | Proteins | Hepatitis | Genotype & phenotype | Historical account | Hepatology | Surgery | Gastroenterology | Endoscopy | Drug dosages | Failure | Genotypes | Creatinine | Liver diseases | Kidneys | Mortality | Patients | Graft rejection | Cirrhosis | Side effects | Hospitals | Womens health | Fibrosis | Interferon | Kidney diseases | Hepatitis C virus | Hepatitis C | Kidney transplantation
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Development of a simple HPLC–UV method for the determination of the hepatitis C virus inhibitor simeprevir in human plasma
by Nannetti, Giulio and Pagni, Silvana and Parisi, Saverio G and Alberti, Alfredo and Loregian, Arianna and Palù, Giorgio
Journal of Pharmaceutical and Biomedical Analysis, ISSN 0731-7085, 03/2016, Volume 121, pp. 197 - 203
A simple high-performance liquid chromatography method for the determination of the hepatitis C virus protease inhibitor simeprevir in human plasma was... 
Therapeutic drug monitoring | HCV protease inhibitor | Simeprevir | Solid-phase extraction | TMC435 | HPLC–UV | HPLC-UV | CHEMISTRY, ANALYTICAL | PLUS RIBAVIRIN | PERFORMANCE LIQUID-CHROMATOGRAPHY | PROTEASE INHIBITOR | HIV | PHARMACOLOGY & PHARMACY | INFECTION | Hepacivirus - drug effects | Simeprevir - chemistry | Simeprevir - blood | Simeprevir - pharmacology | Reproducibility of Results | Chromatography, High Pressure Liquid - methods | Spectrophotometry, Ultraviolet - methods | Drug Stability | Humans | Plasma - chemistry | Hepatitis C virus | Methods | High performance liquid chromatography | Phosphates | Protease inhibitors | Proteases | Analysis | Nitriles | Health aspects
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Efficacy and safety of simeprevir with PegIFN/ribavirin in naïve or experienced patients infected with chronic HCV genotype 4
by Moreno, Christophe and Hezode, Christophe and Marcellin, Patrick and Bourgeois, Stefan and Francque, Sven and Samuel, Didier and Zoulim, Fabien and Grange, Jean-Didier and Shukla, Umesh and Lenz, Oliver and Ouwerkerk-Mahadevan, Sivi and Fevery, Bart and Peeters, Monika and Beumont, Maria and Jessner, Wolfgang
Journal of Hepatology, ISSN 0168-8278, 2015, Volume 62, Issue 5, pp. 1047 - 1055
Background & Aims Simeprevir (SMV) is a once-daily (QD), oral hepatitis C virus (HCV) NS3/4A protease inhibitor approved for treatment of genotype (GT) 1 and... 
Gastroenterology and Hepatology | Simeprevir | Chronic | Response-guided | Efficacy | Safety | TMC435 (10/10) | Hepatitis C virus | Sustained virologic response | Protease inhibitor | Genotype 4 | PLUS RIBAVIRIN | MONOTHERAPY | CHRONIC HEPATITIS-C | PHASE-3 | SUSTAINED VIROLOGICAL RESPONSE | THERAPY | PEGINTERFERON ALPHA-2B | DOUBLE-BLIND | INTERFERON-ALPHA 2A | GASTROENTEROLOGY & HEPATOLOGY | ONCE-DAILY TMC435 | Humans | Middle Aged | Hepacivirus - genetics | Hepatitis C, Chronic - virology | Polyethylene Glycols - adverse effects | Male | Hepatitis C, Chronic - ethnology | Secondary Prevention | Recombinant Proteins - adverse effects | Simeprevir - adverse effects | Simeprevir - administration & dosage | Ribavirin - administration & dosage | Female | Hepacivirus - drug effects | Drug Administration Schedule | RNA, Viral - analysis | Treatment Outcome | Hepatitis C, Chronic - drug therapy | Antiviral Agents - administration & dosage | Polyethylene Glycols - administration & dosage | Recombinant Proteins - administration & dosage | Interferon-alpha - administration & dosage | Drug Therapy, Combination - methods | Ribavirin - adverse effects | Antiviral Agents - adverse effects | Interferon-alpha - adverse effects | Viral Load - drug effects | Viral Load - methods | Genetic aspects | Protease inhibitors | Hepatitis C | Proteases | Health aspects
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Simeprevir, daclatasvir and sofosbuvir for hepatitis C virus‐infected patients with decompensated liver disease
by Lawitz, E and Poordad, F and Gutierrez, J. A and Kakuda, T. N and Picchio, G and Beets, G and Vandevoorde, A and Van Remoortere, P and Jacquemyn, B and Luo, D and Ouwerkerk‐Mahadevan, S and Vijgen, L and Van Eygen, V and Beumont, M
Journal of Viral Hepatitis, ISSN 1352-0504, 04/2017, Volume 24, Issue 4, pp. 287 - 294
Summary Approximately three million individuals in the United States are chronically infected with hepatitis C virus (HCV). Chronic HCV infection may lead to... 
sofosbuvir | simeprevir | hepatitis C | daclatasvir | INFECTIOUS DISEASES | DRUG-INTERACTIONS | RIBAVIRIN | PHASE-3 | NATURAL-HISTORY | LEDIPASVIR | GENOTYPE 1 | VIROLOGY | PLUS SOFOSBUVIR | CIRRHOSIS | HCV | GASTROENTEROLOGY & HEPATOLOGY | Antiviral Agents - pharmacokinetics | United States | Humans | Middle Aged | Imidazoles - administration & dosage | Male | Hepatitis C, Chronic - complications | Imidazoles - pharmacokinetics | Simeprevir - adverse effects | Drug-Related Side Effects and Adverse Reactions - pathology | Simeprevir - pharmacokinetics | Simeprevir - administration & dosage | Adult | Female | Sofosbuvir - pharmacokinetics | Sofosbuvir - adverse effects | Imidazoles - adverse effects | Treatment Outcome | Hepatitis C, Chronic - drug therapy | Antiviral Agents - administration & dosage | Drug-Related Side Effects and Adverse Reactions - epidemiology | Sofosbuvir - administration & dosage | Antiviral Agents - adverse effects | Aged | Hepatic Insufficiency - etiology | Hypertension | Antiviral agents | Medical research | Metabolites | Medicine, Experimental | Hepatitis C virus | Health aspects | Liver cirrhosis
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Daclatasvir combined with sofosbuvir or simeprevir in liver transplant recipients with severe recurrent hepatitis C infection
by Fontana, Robert J and Brown, Robert S and Moreno‐Zamora, Ana and Prieto, Martin and Joshi, Shobha and Londoño, Maria‐Carlota and Herzer, Kerstin and Chacko, Kristina R and Stauber, Rudolf E and Knop, Viola and Jafri, Syed‐Mohammed and Castells, Lluís and Ferenci, Peter and Torti, Carlo and Durand, Christine M and Loiacono, Laura and Lionetti, Raffaella and Bahirwani, Ranjeeta and Weiland, Ola and Mubarak, Abdullah and ElSharkawy, Ahmed M and Stadler, Bernhard and Montalbano, Marzia and Berg, Christoph and Pellicelli, Adriano M and Stenmark, Stephan and Vekeman, Francis and Ionescu‐Ittu, Raluca and Emond, Bruno and Reddy, K. Rajender and Medicinska fakulteten and Infektionssjukdomar and Institutionen för klinisk mikrobiologi and Umeå universitet
Liver Transplantation, ISSN 1527-6465, 04/2016, Volume 22, Issue 4, pp. 446 - 458
Daclatasvir (DCV) is a potent, pangenotypic nonstructural protein 5A inhibitor with demonstrated antiviral efficacy when combined with sofosbuvir (SOF) or... 
SURGERY | INTERFERON-ALPHA-2B | ANTIVIRAL THERAPY | RIBAVIRIN | COMBINATION | VIROLOGICAL RESPONSE | HCV INFECTION | TRANSPLANTATION | GENOTYPE 1 | PLUS SOFOSBUVIR | INHIBITOR | GASTROENTEROLOGY & HEPATOLOGY | COMPASSIONATE USE | Recurrence | Liver Transplantation - adverse effects | Compassionate Use Trials | Humans | Middle Aged | Hepacivirus - genetics | Hepatitis C, Chronic - virology | Imidazoles - administration & dosage | Male | Hepatitis C, Chronic - complications | Simeprevir - therapeutic use | Simeprevir - adverse effects | Simeprevir - administration & dosage | Ribavirin - administration & dosage | Female | Retrospective Studies | Imidazoles - therapeutic use | Sofosbuvir - adverse effects | Sofosbuvir - therapeutic use | Hepacivirus - isolation & purification | Liver Cirrhosis - etiology | Antiviral Agents - therapeutic use | Imidazoles - adverse effects | Ribavirin - therapeutic use | Genotype | Treatment Outcome | Hepatitis C, Chronic - drug therapy | Antiviral Agents - administration & dosage | Drug Therapy, Combination - methods | Sofosbuvir - administration & dosage | Ribavirin - adverse effects | Antiviral Agents - adverse effects | Liver Cirrhosis - pathology | Liver Diseases - surgery | Aged | Infectious Medicine | Clinical Medicine | Medical and Health Sciences | Klinisk medicin | Medicin och hälsovetenskap | Infektionsmedicin
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text New Hepatitis C Therapies: The Toolbox, Strategies, and Challenges
by Pawlotsky, Jean–Michel
Gastroenterology, ISSN 0016-5085, 2014, Volume 146, Issue 5, pp. 1176 - 1192
Therapy for hepatitis C is undergoing a revolution. Several new drugs against the hepatitis C virus (HCV) have reached the market and many others, including... 
Gastroenterology and Hepatology | Daclatasvir | Simeprevir | Direct-Acting Antivirals | Interferon-Free Regimens | Sofosbuvir | Keywords | PEGYLATED INTERFERON ALPHA-2A | PHASE-III TRIAL | NS5A INHIBITOR | REPLICATION COMPLEX INHIBITOR | SOFOSBUVIR PLUS RIBAVIRIN | TREATMENT-EXPERIENCED PATIENTS | HCV-GENOTYPE 1 | SIMEPREVIR TMC435 | GASTROENTEROLOGY & HEPATOLOGY | TREATMENT-NAIVE PATIENTS | NS3 PROTEASE INHIBITOR | Drug Costs | Hepacivirus - drug effects | Prevalence | Global Health | Hepatitis C - drug therapy | Antiviral Agents - therapeutic use | Humans | Drug Resistance, Viral | Hepacivirus - genetics | Hepatitis C - economics | Genotype | Treatment Outcome | Patient Selection | Hepatitis C - diagnosis | Phenotype | Health Services Accessibility | Antiviral Agents - adverse effects | Hepatitis C - epidemiology | Healthcare Disparities | Developing Countries | Antiviral Agents - economics | Drug Therapy, Combination | Antiviral agents | Biological response modifiers | Hepatitis C virus | Hepatitis C | Health aspects
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
13. Full Text Direct-acting antivirals for chronic hepatitis C
by Jakobsen, Janus C and Nielsen, Emil Eik and Feinberg, Joshua and Katakam, Kiran Kumar and Fobian, Kristina and Hauser, Goran and Poropat, Goran and Djurisic, Snezana and Weiss, Karl Heinz and Bjelakovic, Milica and Bjelakovic, Goran and Klingenberg, Sarah Louise and Liu, Jian Ping and Nikolova, Dimitrinka and Koretz, Ronald L and Gluud, Christian
Cochrane Database of Systematic Reviews, ISSN 1469-493X, 06/2017, Volume 2017, Issue 6, pp. CD012143 - CD012143
Millions of people worldwide suffer from hepatitis C, which can lead to severe liver disease, liver cancer, and death. Direct-acting antivirals (DAAs) are... 
Hepacivirus - drug effects | Nucleic Acid Synthesis Inhibitors - therapeutic use | Nucleic Acid Synthesis Inhibitors - adverse effects | Antiviral Agents - therapeutic use | Humans | Hepatitis C, Chronic - complications | Hepatitis C, Chronic - drug therapy | Hepatitis C, Chronic - mortality | Simeprevir - therapeutic use | Cause of Death | Safety-Based Drug Withdrawals | Simeprevir - adverse effects | Randomized Controlled Trials as Topic | Placebos - therapeutic use | Antiviral Agents - adverse effects | Protease Inhibitors - adverse effects | Protease Inhibitors - therapeutic use | SUSTAINED VIROLOGICAL RESPONSE | PLUS PEGINTERFERON ALPHA-2B/RIBAVIRIN | PHASE-III TRIAL | NONNUCLEOSIDE POLYMERASE INHIBITOR | MEDICINE, GENERAL & INTERNAL | PEGYLATED INTERFERON ALPHA-2A | HCV GENOTYPE 1 | TREATMENT-EXPERIENCED PATIENTS | NS3/4A PROTEASE INHIBITOR | TREATMENT-NAIVE PATIENTS | PATIENT-REPORTED OUTCOMES | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights